

Short Communications

Inhibitory effects of *dl*-Puerol A in the root of *Sophora japonica* on copper ion-induced protein oxidative modification of mouse brain homogenate *in vitro*Shizuo Toda^{1,*} and Yoshiaki Shirataki²

¹Department of Pharmaceutical Science, Kansai College of Oriental Medicine, 2-11-1 Wakaba, Kumatori, Sen-nan, Osaka 590-0482, Japan; ²Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan

SUMMARY

The inhibitory effect of *dl*-puerol A as but-2-enolide isolated from *Sophora japonica* was investigated on copper ion-induced protein oxidative modification *in vitro*. It inhibited copper-induced protein oxidative modification. However, its inhibitory effect was a little weaker than that of *dl*- α -tocopherol as an antioxidant.

The results demonstrated that *dl*-puerol A, one of but-2-enolides, might be of use in the oxidative stress.

Key words: Copper; Protein oxidative modification; *dl*-puerol A; *Sophora japonica*

Copper ion induces to generation of oxygen free-radical species. They have been a well-known cause of protein oxidative modification, leading to pathological conditions such as Wilson's disease (Halvorsen *et al.*, 1996). Recently, the natural antioxidants have been found in many plants, such as spices, vegetables and herbs (Nakatani, 2000). We found that isoflavones, licoisoflavones A and B have the antioxidative effects (Toda and Shirataki, 2002). These isoflavones were isolated from *Sophora plant* (Shirataki *et al.*, 1988). *dl*-Puerol A as but-2-enolide was isolated from *Sophora japonica*, which has been used in Traditional Medicine as a hemostatic (Shirataki *et al.*, 1987; Nohara *et al.*, 1993). In this

paper, we investigated the inhibitory effect of *dl*-puerol A isolated from *Sophora japonica*, on copper ion-induced protein oxidative modification *in vitro*.

Sophora japonica L. (Leguminosae), were collected in Koishikawa Botanical Garden, Tokyo University in November 1972. The plants were verified by professor Yoshiaki Shirataki, Josai University in Japan. A voucher specimen was deposited at the Herbarium in Josai University in Japan.

Male ddY mice weighing between 25 and 30 g, 6-7 weeks old were obtained from SLC, Shizuoka, Japan. They were housed in a room maintained at 25 °C with a relative humidity of 60 %.

Copper chloride, 2,4-dithionitrophenylhydrazine, 5,5'-dithiobis(2-nitrobenzoic) acid (DTNB), disodium salt of ethylenediaminetetraacetic acid (EDTA), *dl*- α -tocopherol and urea were obtained from Wako Pure Chemicals Co., Osaka, Japan. Other

*Correspondence: Shizuo Toda, Department of Pharmaceutical Science, Kansai College of Oriental Medicine, 2-11-1 Wakaba, Kumatori, Sen-nan, Osaka 590-0482, Japan. Tel: +81-724-53-8251; Fax:+81-724-53-8767; E-mail: toda@kansai.ac.jp

common laboratory reagents were of analytical grade.

The dried roots of *Sophora japonica* L. were extracted 3 times with boiling methanol. The ether soluble part of the methanol extract was column chromatographed on silica gel by using benzene-ethyl acetate as eluents and checked by thin layer chromatography (solvent: benzen-ethyl acetate=1:1). *dl*-Puerol A was eluted in this chromatography. Crude *dl*-puerol A was subjected to rechromatography on silica gel to yield *dl*-puerol (Shirataki et al., 1987; Nohara et al., 1993).

The brains were removed from the mice immediately after killing and were subjected to homogenization in ice-cold 50 mM Tris-HCl buffer at pH 7.4, using a Potter-Elvehjem homogenizer. The brain homogenate containing 250 g protein/mL was prepared in the same buffer. The protein content of the brain homogenate was established by the procedure described by Lowry (Lowry et al., 1951).

The brain homogenate described in the previous section was incubated to a total volume of 0.3 mL with 250 M copper chloride in 50 mM Tris-HCl pH 7.4 buffer. The reaction mixture was incubated at 37 °C for 2 h and then 1.6 mL of 0.125 M, pH 8.0 phosphate buffer containing 12.5 mM EDTA, 10.0 M urea and 0.1 mL of pH 7.0 phosphate buffer containing 10 mM DTNB were added. The resulting solution was allowed to stand at room temperature for 5 min, and then the absorbance of the cystein SH residue was read at 412 nm (Ellman, 1959). The inhibitory ratio of the test sample was evaluated by the following equation: I.R.%=(Δ Cys-SH/ Δ Cys-SH[°]). Where I.R.% is the inhibitory ratio, (%). Δ Cys-SH is the Cys-SH residue in treated sample Cys-SH residue in reaction blank and Δ Cys-SH[°] is Cys-SH residue before incubation Cys-SH residue, untreated blank.

The inhibitory ratio was plotted against the

log [F1] ([F1] = concentration of sample). The dose-response data were used to corresponding IC₅₀.

The values were expressed as the mean standard error of five experiments. The results were analysed by the non-parametric ANOVA-Scheffe *f*-test.

The results presented in Table 1 show that the percent inhibitory ratios of the inhibitory effects of *dl*-puerol A and *dl*- α -tocopherol as an antioxidant reached 89.8 ± 2.8% and 100 % at a concentration of 100 M, and that they increased in a concentration-dependent manner. Inhibitory ratios are lower than those of *dl*- α -tocopherol at concentrations of 100, 10 and 1.0 M (Table 1). The IC₅₀ values of *dl*-puerol A and *dl*- α -tocopherol are 95.4 and 11.7 M, respectively.

The results showed that *dl*-puerol inhibited copper-induced protein oxidative modification. However, its inhibitory effect was a little weaker than that of *dl*- α -tocopherol as an antioxidant. *dl*-Puerol A was isolated from *Sophora japonica* (Shirataki et al., 1987; Nohara et al., 1993). *dl*-Puerol A is one of butenolides (Fig. 1). Three flavonol triglucosides, kaempferol 3-O- α -1-rhamnopyranosyl(1→6)- β -D-gluopyranosyl(1→2)- β -D-glucopyranoside, kaempferol 3-O-[α -1-rhamnopyranosyl (1→6)]-[β -D-gluopyranosyl(1→2)]- β -D-glucopyranoside and kaempferol 3-O- β -D-glucopyranosyl-(1→2)- β -D-glucopyranoside-7-O- α -1-rhamnopyranoside were isolated from *Sophora japonica* and identified as antioxidants (Tang et al., 2002). Rutin from *Sophora japonica* has been found to have antioxidant activity (Paniwnyk et al., 2001). A butenolide compound, (1E, 3E, 5E, 7E)-5-hydroxy-4-(8-phenyl-1,3,5,7-octatetraenyl)-2(5H)-furanone has been shown to have strong anti-tumor activity (Satomi et al., 1992). Another butanolide, 2-buten-4-olide, has been also shown to inhibit type II collagen-induced arthritis in Lewis rats (Takeoka et al., 1993). There have been no reports about the

antioxidant effects of butenolides isolated from *Sophora japonica* like *dl*-puerol A.

The present results demonstrated that butenolide as *dl*-puerol A isolated from *Sophora japonica* has inhibitory effect on copper-induced protein oxidative modification. There have been never reports about antioxidant activities of butenolides.

Table 1. Inhibitory effects of *dl*-puerol A on copper ion-induced protein oxidative modification of mouse brain homogenate *in vitro*

Test sample	Concentration (M)	Inhibitory ratio (%)
<i>dl</i> -puerol A	0.1	9.3 ± 2.5
	1.0	14.4 ± 3.5 ^c
	10	37.3 ± 4.4 ^b
	100	89.8 ± 2.8 ^a
<i>dl</i> - α -tocopherol	0.1	13.4 ± 6.7
	1.0	44.7 ± 2.6 ^c
	10	95.6 ± 2.8 ^b
	100	100 ^a

The inhibitory ratio, in %, is reported as the mean ± SE of five experiments. ^{a,b,c}*P*<0.01




Fig. 1. Chemical structure of *dl*-Puerol A

REFERENCES

Ellman GL. (1959) Tissue sulfhydryl group. *Arch. Biochem. Biophys.* **82**, 70-77.

Halvorsen B, Brude I, Devon CA. (1996) Effects homocystein on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. *J. Lipid Res.* **37**, 1591-1600.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951) Protein measurement with Folin phenol reagent. *J. Biol. Chem.* **193**, 265-275.

Nakatani N. (2000) Phenolic antioxidants from herbs and spices. *Biofactor* **13**, 141-146.

Nohara T, Kinjo J, Furusawa J, Sakai Y, Inoue M, Shirataki Y, Ishibashi Y, Yokoe I, Kimatsu M. (1993) But-2-anolides from *Pueraria lobata* and revised structures of puerosode A, B, and sophoraside A. *Phytochem.* **33**, 1207-1210.

Paniwnyk L, Beaufoy E, Lorimer JP, Mason TJ. (2001) The extraction of rutin from flower buds of *Sophora japonica*. *Ultra Sonochem.* **8**, 299-301.

Satomi Y, Nishino, Iwashima A, Torihara M, Tamai Y, Ito M. (1992) Inhibitory effects (1E, 3E, 5E, 7E)-5-hydroxy-4-(8-phenyl-1,3,5,7-octatetraenyl)-2(5H)-furanone on proliferation of human malignant tumor cells. *Anticancer Drug Des.* **7**, 169-179.

Shirataki Y, Tagaya Y, Yo koe I, Komatsu M. (1987) Sophoraside A, a new aromatic glycoside from the roots of *Sophora japonica*. *Chem. Pharm. Bull.* **35**, 1637-1640.

Shirataki Y, Yokoe I, Noguchi T, Tomimori T, Komatsu M. (1988) Studies on the constituents of *Sophora* species. XXII. Constituents of the root of *Sophora mooracraftiana* BETH ex BAKER. *Chem. Pharm. Bull.* **36**, 2220-2225.

Shirataki Y, Tanaka T, Ohyama M, Toda S, Inuma M. (2002) Stilbene oligomers in root *Sophora mooracraftiana*. *Natural Med.* **56**, 139-142.

Takeoka Y, Naiki M, Taguchi N, Imai H, Kurimoto Y, Morita S, Suehiro S. (1993) 2Buten4olide inhibits type II collagen-induced arthritis in Lewis rats. *Int. J. Immunopharmacol.* **15**, 803-810.

Tang YP, Li YF, Hu J, Lou FC. (2002) Isolation and identification of antioxidants from *Sopjora japonica*. *J. Asian Nat. Prod. Res.* **4**, 123-128.

Toda S, Shirataki Y. (2002) Inhibitory effects of

isoflavones in *Sophora mooracroftiana* on lipid peroxidation by superoxide. *Pharmaceut. Biol.* **40**, 422-424.